← Back to Search

Nonsteroidal Anti-Inflammatory Drug

Voltaren Gel for Knee Osteoarthritis Pain

Phase 4
Recruiting
Research Sponsored by HALEON
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Participant is male or female between the ages of 40 and 85 years
Participant with self-reported knee pain, with a score of >=40mm and <=70mm on the pain intensity visual analogue scale at the time of Informed Consent Form (ICF) signature
Must not have
Participant with knee skin area pathological condition preventing application of product to the skin
Participant with confirmed rheumatologic disease
Timeline
Screening 3 weeks
Treatment Varies
Follow Up days 7, 14 and 21
Awards & highlights

Summary

This trial aims to see if using diclofenac gel on the skin can help people with knee osteoarthritis move better, be more active, and improve their overall quality of life including sleep

Who is the study for?
This trial is for men and women aged 40-85 with mild to moderate knee pain from osteoarthritis, scoring 40-70mm on a pain scale. Participants must be willing to use Voltaren Gel as directed, wear an activity tracker continuously, and have radiological proof of osteoarthritis within the last three years.Check my eligibility
What is being tested?
The study tests how different concentrations of Voltaren Gel (diclofenac) affect mobility and quality of life in those with knee osteoarthritis. It measures improvements in movement, sleep, mood, and daily activities.See study design
What are the potential side effects?
Voltaren Gel may cause side effects like skin irritation at the application site, digestive issues such as nausea or indigestion, liver function changes, kidney problems or increased blood pressure.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am between 40 and 85 years old.
Select...
I have knee pain rated between 40mm and 70mm on a pain scale.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I cannot apply products to my knee due to a skin condition.
Select...
I have been diagnosed with a rheumatic disease.
Select...
I currently have an active infection.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~days 7, 14 and 21
This trial's timeline: 3 weeks for screening, Varies for treatment, and days 7, 14 and 21 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change from Baseline in the Average Minutes of MVPA at Week 2
Change from Baseline in the Average Minutes of MVPA at Week 3
Change from Baseline in the Average Minutes of Moderate and Vigorous Physical Activity (MVPA) at Week 1
Secondary outcome measures
Change from Baseline in Daily Average Number of Stairs Climbed/Descended at Days 7, 14 and 21
Change from Baseline in Daily Average Number of Steps Taken at Days 7, 14 and 21
Change from Baseline in Gait, Assessed Through Speed and Step Irregularity at Days 7, 14 and 21
+10 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: Voltaren GelExperimental Treatment3 Interventions
Participants will use Voltaren Gel 1 percent (%) (in the US) or Voltaren Gel 1.16% or Voltaren Gel 2.32% (in the EU) topically, applied daily as per label and leaflet instructions for up to 21 days. Participants will be instructed to wear Actigraph device on the wrist as per label, leaflet or site-specific instructions post training throughout the day for up to 21 days.

Find a Location

Who is running the clinical trial?

HALEONLead Sponsor
29 Previous Clinical Trials
3,977 Total Patients Enrolled
3 Trials studying Pain
189 Patients Enrolled for Pain
~97 spots leftby Nov 2024